Safety and feasibility of collateral blood flow augmentation after intravenous thrombolysis

Stroke. 2011 Apr;42(4):1135-7. doi: 10.1161/STROKEAHA.110.607846. Epub 2011 Feb 24.


Background and purpose: Collateral flow augmentation using partial aortic occlusion may improve cerebral perfusion in acute stroke. We assessed the safety and feasibility of partial aortic occlusion immediately after intravenous tissue plasminogen activator.

Methods: We conducted an open-label pilot study of partial aortic occlusion after thrombolysis. The primary end point was all serious adverse events within 30 days of treatment.

Results: None of the 22 patients enrolled developed symptomatic parenchymal hemorrhages. Asymptomatic hemorrhagic transformation occurred in 9 patients. Procedure-related adverse events were limited to groin complications (n=13). Seventy-seven percent of patients experienced neurological improvement (≥4-point improvement of the National Institutes of Health Stroke Scale score).

Conclusions: Partial aortic occlusion as an adjunct to thrombolysis in the treatment of acute stroke appears safe. Studies aimed at determining the efficacy of this therapeutic approach are warranted.

Clinical trial registration information: URL: Unique Identifier: NCT01006993.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Aorta, Abdominal / physiopathology
  • Balloon Occlusion / adverse effects
  • Balloon Occlusion / instrumentation
  • Balloon Occlusion / methods*
  • Cerebrovascular Circulation / drug effects
  • Cerebrovascular Circulation / physiology*
  • Combined Modality Therapy / instrumentation
  • Combined Modality Therapy / methods*
  • Female
  • Fibrinolytic Agents / administration & dosage
  • Humans
  • Hypoxia-Ischemia, Brain / physiopathology
  • Hypoxia-Ischemia, Brain / therapy*
  • Infusions, Intravenous / methods
  • Male
  • Middle Aged
  • Pilot Projects
  • Thrombolytic Therapy / methods*
  • Tissue Plasminogen Activator / administration & dosage


  • Fibrinolytic Agents
  • Tissue Plasminogen Activator

Associated data